-
公开(公告)号:US5059600A
公开(公告)日:1991-10-22
申请号:US331923
申请日:1989-03-31
IPC分类号: A61K31/445 , A61K31/495 , A61K31/54 , A61K31/55
CPC分类号: A61K31/55 , A61K31/445 , A61K31/495 , A61K31/54
摘要: A method for teating habit disorders in a human patient comprising administering to the patient an anti-habitual amount of a pharmaceutically active compound, which results in activation of a brain reward system, e.g., flupenthixol, or esters thereof or pharmaceutically acceptable salts thereof, either alone or in admixture with a physiologically acceptable diluent.
摘要翻译: 一种在人类患者中挑选习惯障碍的方法,包括向患者施用抗习惯量的药物活性化合物,其导致脑回报系统的活化,例如氟哌噻吨或其酯或其药学上可接受的盐, 单独或与生理上可接受的稀释剂混合。
-
公开(公告)号:US5114942A
公开(公告)日:1992-05-19
申请号:US641378
申请日:1991-01-15
IPC分类号: A61K31/445 , A61K31/495 , A61K31/54 , A61K31/55
CPC分类号: A61K31/445 , A61K31/495 , A61K31/54 , A61K31/55
摘要: A method for treating habit disorders in a human patient comprising administering to the patient an antihabitual amount of a pharmaceutically active compound, which results in activation of a brain reward system, e.g., flupenthixol, or esters thereof or pharmaceutically acceptable salts thereof, either alone or in admixture with a physiologically acceptable diluent.
摘要翻译: 一种用于治疗人类患者的习惯障碍的方法,包括向患者施用抗自由量的药物活性化合物,其导致脑回报系统(例如氟哌噻吨或其酯或其药学上可接受的盐)的活化,单独或 与生理上可接受的稀释剂混合。
-
公开(公告)号:US5223497A
公开(公告)日:1993-06-29
申请号:US846785
申请日:1992-03-04
IPC分类号: A61K31/445 , A61K31/495 , A61K31/54 , A61K31/55
CPC分类号: A61K31/445 , A61K31/495 , A61K31/54 , A61K31/55
摘要: A method for treating habit disorders in a human patient comprising administering to the patient an anti-habitual amount of a pharmaceutically active compound, which results in activation of a brain reward system, e.g., flupenthixol, or esters thereof or pharmaceutically acceptable salts thereof, either alone or in admixture with a physiologically acceptable diluent.
摘要翻译: 一种用于治疗人类患者的习惯障碍的方法,包括向患者施用抗习惯量的药物活性化合物,其导致脑回报系统的活化,例如氟哌噻吨或其酯或其药学上可接受的盐, 单独或与生理上可接受的稀释剂混合。
-
公开(公告)号:US06281213B1
公开(公告)日:2001-08-28
申请号:US09251002
申请日:1999-02-16
IPC分类号: A61K31495
CPC分类号: A61K31/495 , A61K31/50
摘要: Psychomotor stimulant addiction in humans is treated by administering to a human patient before or during a hypodopaminergic “crash” following the psychomotor stimulant induced hyperdopaminergic high or within a period of 3 hours to 21 days prior thereto, a dosage of a pharmaceutically active neuroleptic compound effective to produce aversion to any psychomotor stimulant taken within this period.
摘要翻译: 精神运动兴奋剂成瘾在人类中通过在精神运动兴奋剂诱导的高度多巴胺能高或在其之前3小时至21天的时间段内或之前或之后给予人类患者进行治疗,剂量的药学活性精神抑制药物有效 在此期间对任何精神运动兴奋剂产生厌恶。
-
公开(公告)号:US5185329A
公开(公告)日:1993-02-09
申请号:US791714
申请日:1991-11-14
申请人: Frank H. Gawin , Robert Byck , Marc Alderdice , Jeffrey Schwimmer
发明人: Frank H. Gawin , Robert Byck , Marc Alderdice , Jeffrey Schwimmer
IPC分类号: A61K31/40 , A61K31/425 , A61K31/435 , A61K31/505
CPC分类号: A61K31/435 , A61K31/40 , A61K31/425 , A61K31/505 , Y10S514/811 , Y10S514/813
摘要: Certain azapirone compounds and their pharmaceutically acceptable salts are useful in the treatment of substance addiction.
摘要翻译: 某些azapirone化合物及其药学上可接受的盐可用于治疗物质成瘾。
-
公开(公告)号:US5468749A
公开(公告)日:1995-11-21
申请号:US367823
申请日:1989-06-16
申请人: Frank H. Gawin , Robert Byck , Marc Alderdice , Jeffrey Schwimmer
发明人: Frank H. Gawin , Robert Byck , Marc Alderdice , Jeffrey Schwimmer
IPC分类号: A61K31/40 , A61K31/425 , A61K31/435 , A61K31/505 , A61K31/50 , A61K31/495
CPC分类号: A61K31/505 , A61K31/40 , A61K31/425 , A61K31/435 , Y10S514/813
摘要: Certain azapirone compounds and their pharmaceutically acceptable salts are useful in the treatment of substance addiction.
摘要翻译: 某些azapirone化合物及其药学上可接受的盐可用于治疗物质成瘾。
-
-
-
-
-